ERMP1

Summary

ERMP1 (endoplasmic reticulum metallopeptidase 1, HGNC:23703) is a protein-coding gene on chromosome 9p24.1, encoding Endoplasmic reticulum metallopeptidase 1 (Q7Z2K6). Within the ovary, required for the organization of somatic cells and oocytes into discrete follicular structures.

Predicted to enable metal ion binding activity and metalloexopeptidase activity. Involved in cellular response to oxidative stress. Acts upstream of or within endoplasmic reticulum unfolded protein response. Located in membrane.

Source: NCBI Gene 79956 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 159 total — 2 pathogenic
• Phenotypes (HPO): 1
• Druggable target: yes
• MANE Select transcript: NM_024896

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:23703
Approved symbol	ERMP1
Name	endoplasmic reticulum metallopeptidase 1
Location	9p24.1
Locus type	gene with protein product
Status	Approved
Aliases	FLJ23309, FXNA
Ensembl gene	ENSG00000099219
Ensembl biotype	protein_coding
OMIM	611156
Entrez	79956

Gene structure

Transcript identifiers

Ensembl transcripts: 39 — 18 protein_coding, 16 nonsense_mediated_decay, 4 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000214893, ENST00000339450, ENST00000462592, ENST00000475005, ENST00000487088, ENST00000489219, ENST00000684950, ENST00000685462, ENST00000686418, ENST00000688202, ENST00000688283, ENST00000688887, ENST00000688899, ENST00000689030, ENST00000689259, ENST00000689268, ENST00000689364, ENST00000689671, ENST00000689742, ENST00000690037, ENST00000690284, ENST00000690648, ENST00000690753, ENST00000691058, ENST00000691251, ENST00000691560, ENST00000692524, ENST00000692974, ENST00000693487, ENST00000693638, ENST00000908727, ENST00000908728, ENST00000908729, ENST00000908730, ENST00000914774, ENST00000914775, ENST00000914776, ENST00000943573, ENST00000943574

RefSeq mRNA: 2 — MANE Select: NM_024896 NM_001410952, NM_024896

CCDS: CCDS34983, CCDS94378

Canonical transcript exons

ENST00000339450 — 15 exons

Exon	Start	End
ENSE00001659147	5784572	5787308
ENSE00001838248	5832690	5833117
ENSE00003459953	5787430	5787593
ENSE00003463105	5797817	5797932
ENSE00003495105	5825092	5825219
ENSE00003496114	5823896	5824001
ENSE00003506226	5801176	5801328
ENSE00003515678	5805027	5805217
ENSE00003532137	5798806	5799008
ENSE00003532567	5830727	5831028
ENSE00003621862	5805611	5805785
ENSE00003658784	5810011	5810231
ENSE00003664270	5812889	5813035
ENSE00003666426	5811111	5811323
ENSE00003669659	5812125	5812217

Expression profiles

Bgee: expression breadth ubiquitous, 284 present calls, max score 99.15.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 8.8026 / max 261.2606, expressed in 1647 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
99841	8.5527	1644
99840	0.2377	134
99839	0.0122	4

Top tissues by expression

292 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
palpebral conjunctiva	UBERON:0001812	99.15	gold quality
renal medulla	UBERON:0000362	98.22	gold quality
esophagus squamous epithelium	UBERON:0006920	98.08	gold quality
epithelium of esophagus	UBERON:0001976	96.92	gold quality
inferior vagus X ganglion	UBERON:0005363	96.77	gold quality
urethra	UBERON:0000057	96.76	gold quality
secondary oocyte	CL:0000655	96.40	gold quality
decidua	UBERON:0002450	96.39	gold quality
oocyte	CL:0000023	96.02	gold quality
adrenal tissue	UBERON:0018303	95.98	gold quality
pigmented layer of retina	UBERON:0001782	95.64	gold quality
retina	UBERON:0000966	95.62	gold quality
subthalamic nucleus	UBERON:0001906	95.57	gold quality
germinal epithelium of ovary	UBERON:0001304	95.50	gold quality
medial globus pallidus	UBERON:0002477	95.40	gold quality
oral cavity	UBERON:0000167	95.37	gold quality
substantia nigra pars reticulata	UBERON:0001966	95.34	gold quality
epithelium of nasopharynx	UBERON:0001951	95.32	gold quality
pons	UBERON:0000988	95.09	gold quality
globus pallidus	UBERON:0001875	95.05	gold quality
substantia nigra pars compacta	UBERON:0001965	94.85	gold quality
penis	UBERON:0000989	94.81	gold quality
squamous epithelium	UBERON:0006914	94.67	gold quality
dorsal plus ventral thalamus	UBERON:0001897	94.35	gold quality
superior vestibular nucleus	UBERON:0007227	94.35	gold quality
mucosa of sigmoid colon	UBERON:0004993	94.25	gold quality
sperm	CL:0000019	94.24	gold quality
mammalian vulva	UBERON:0000997	94.07	gold quality
colonic mucosa	UBERON:0000317	94.04	gold quality
pharyngeal mucosa	UBERON:0000355	93.69	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	7.40

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

129 targeting ERMP1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-3910	99.95	71.13	2227
HSA-MIR-6835-3P	99.93	70.49	2904
HSA-MIR-4760-3P	99.93	70.50	2385
HSA-MIR-539-5P	99.93	70.30	2855
HSA-MIR-205-3P	99.92	69.92	3165
HSA-MIR-6768-5P	99.92	67.36	1942
HSA-MIR-1305	99.91	71.43	3443
HSA-MIR-652-5P	99.91	67.49	505
HSA-MIR-3529-3P	99.90	73.55	3045
HSA-MIR-124-3P	99.89	73.74	3043
HSA-MIR-506-3P	99.89	73.55	3057
HSA-MIR-345-3P	99.89	70.23	1421
HSA-MIR-30A-3P	99.87	69.74	2928
HSA-MIR-30D-3P	99.87	69.92	2917
HSA-MIR-30E-3P	99.87	69.68	2942
HSA-MIR-4698	99.84	71.41	4303
HSA-MIR-3133	99.81	70.92	3506

Literature-anchored findings (GeneRIF, showing 2)

• Functional analysis of the rat Fxna ortholog. (PMID:17267443)
• High expression of ERMP1 is correlated with cancer. (PMID:27566589)

Cross-species orthologs

16 orthologs

Organism	Symbol	Gene ID
		ENSDARG00000107947
danio_rerio		ENSDARG00000110653
mus_musculus	Ermp1	ENSMUSG00000046324
rattus_norvegicus	Ermp1	ENSRNOG00000010915
drosophila_melanogaster	CG13160	FBGN0033720
drosophila_melanogaster	CG11961	FBGN0034436
drosophila_melanogaster	CG10051	FBGN0034437
drosophila_melanogaster	CG9416	FBGN0034438
drosophila_melanogaster	CG10062	FBGN0034439
drosophila_melanogaster	CG10073	FBGN0034440
drosophila_melanogaster	CG10081	FBGN0034441
drosophila_melanogaster	CG30043	FBGN0050043
drosophila_melanogaster	CG30047	FBGN0050047
drosophila_melanogaster	CG30049	FBGN0050049
drosophila_melanogaster	CG33012	FBGN0053012
caenorhabditis_elegans		WBGENE00015206

Protein

Protein identifiers

Endoplasmic reticulum metallopeptidase 1 — Q7Z2K6 (reviewed: Q7Z2K6)

Alternative names: Felix-ina

All UniProt accessions (15): Q7Z2K6, A0A0C4DGF0, A0A8I5KNY4, A0A8I5KR85, A0A8I5KUT1, A0A8I5KWW9, A0A8I5KXJ0, A0A8I5KYJ3, A0A8I5QJH1, A0A8I5QJM6, A0A8I5QJQ5, A0A8I5QJT4, A0A8I5QKK8, A0A8I5QL16, E7ER77

UniProt curated annotations — full annotation on UniProt →

Function. Within the ovary, required for the organization of somatic cells and oocytes into discrete follicular structures.

Subcellular location. Endoplasmic reticulum membrane.

Cofactor. Binds 2 Zn(2+) ions per subunit.

Similarity. Belongs to the peptidase M28 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q7Z2K6-1	1	yes
Q7Z2K6-2	2

RefSeq proteins (2): NP_001397881, NP_079172* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007484	Peptidase_M28	Domain
IPR045175	M28_fam	Family
IPR048024	Fxna-like_M28_dom	Domain
IPR053973	ERMP1-like_C	Domain
IPR053974	ERMP1_1-A_TM	Domain

Pfam: PF04389, PF22248, PF22249

UniProt features (39 total): topological domain 10, transmembrane region 9, binding site 6, glycosylation site 2, splice variant 2, sequence conflict 2, chain 1, region of interest 1, compositionally biased region 1, active site 1, site 1, modified residue 1, disulfide bond 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q7Z2K6-F1	89.45	0.80

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (2): 251 (proton acceptor); 353 (transition state stabilizer)

Ligand- & substrate-binding residues (6): 205; 217; 217; 252; 278; 354

Post-translational modifications (1): 1

Disulfide bonds (1): 204–222

Glycosylation sites (2): 182, 730

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 180 (showing top): AGGAAGC_MIR5163P, BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, GOMF_METALLOPEPTIDASE_ACTIVITY, GOBP_RESPONSE_TO_ENDOPLASMIC_RETICULUM_STRESS, GAUSSMANN_MLL_AF4_FUSION_TARGETS_C_DN, GOBP_CELLULAR_RESPONSE_TO_TOPOLOGICALLY_INCORRECT_PROTEIN, PATIL_LIVER_CANCER, SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_UP, PYEON_CANCER_HEAD_AND_NECK_VS_CERVICAL_UP, KIM_GERMINAL_CENTER_T_HELPER_UP, NAKAMURA_TUMOR_ZONE_PERIPHERAL_VS_CENTRAL_DN, JAATINEN_HEMATOPOIETIC_STEM_CELL_UP, ONDER_CDH1_SIGNALING_VIA_CTNNB1, TGCCTTA_MIR124A, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_DN

GO Biological Process (3): proteolysis (GO:0006508), endoplasmic reticulum unfolded protein response (GO:0030968), cellular response to oxidative stress (GO:0034599)

GO Molecular Function (6): metalloexopeptidase activity (GO:0008235), metal ion binding (GO:0046872), protein binding (GO:0005515), peptidase activity (GO:0008233), metallopeptidase activity (GO:0008237), hydrolase activity (GO:0016787)

GO Cellular Component (3): endoplasmic reticulum membrane (GO:0005789), membrane (GO:0016020), endoplasmic reticulum (GO:0005783)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein metabolic process	1
cellular response to unfolded protein	1
response to endoplasmic reticulum stress	1
intracellular signal transduction	1
response to oxidative stress	1
cellular response to chemical stress	1
metallopeptidase activity	1
exopeptidase activity	1
cation binding	1
binding	1
hydrolase activity	1
catalytic activity, acting on a protein	1
peptidase activity	1
catalytic activity	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
cellular anatomical structure	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

850 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ERMP1	RIC1	Q4ADV7	659
ERMP1	BRD10	Q5HYC2	602
ERMP1	UPP2	O95045	529
ERMP1	COMMD2	Q86X83	519
ERMP1	UPP1	Q16831	490
ERMP1	TOR1AIP1	Q5JTV8	474
ERMP1	COMMD4	Q9H0A8	464
ERMP1	UHRF2	Q96PU4	462
ERMP1	PITRM1	Q5JRX3	462
ERMP1	MRPL38	Q96DV4	456
ERMP1	TMTC2	Q8N394	453
ERMP1	WDR81	Q562E7	453
ERMP1	CHST14	Q8NCH0	450
ERMP1	TASP1	Q9H6P5	428
ERMP1	DMRT3	Q9NQL9	427

IntAct

276 interactions, top by confidence:

A	B	Type	Score
YWHAH	FAM83G	psi-mi:“MI:0914”(association)	0.710
NIPAL1	ESYT2	psi-mi:“MI:0914”(association)	0.640
ERMP1	CD200R1	psi-mi:“MI:0915”(physical association)	0.560
ERMP1	GPR42	psi-mi:“MI:0915”(physical association)	0.560
ERMP1	SLC22A23	psi-mi:“MI:0915”(physical association)	0.560
ERMP1	TMEM45A	psi-mi:“MI:0915”(physical association)	0.560
BSCL2	ERMP1	psi-mi:“MI:0915”(physical association)	0.560
ERMP1	ATP1B4	psi-mi:“MI:0915”(physical association)	0.560
ERMP1	SLC13A4	psi-mi:“MI:0915”(physical association)	0.560
ERMP1	TMEM237	psi-mi:“MI:0915”(physical association)	0.560
ERMP1	CREB3L1	psi-mi:“MI:0915”(physical association)	0.560
KLRC1	ERMP1	psi-mi:“MI:0915”(physical association)	0.560
ERMP1	BCL2L13	psi-mi:“MI:0915”(physical association)	0.560
ERMP1	CLEC2D	psi-mi:“MI:0915”(physical association)	0.560
ERMP1	SPAG4	psi-mi:“MI:0915”(physical association)	0.560
	ERMP1	psi-mi:“MI:0915”(physical association)	0.560
AQP6	ERMP1	psi-mi:“MI:0915”(physical association)	0.560
FAM209A	ERMP1	psi-mi:“MI:0915”(physical association)	0.560
CLDN5	ERMP1	psi-mi:“MI:0915”(physical association)	0.560
ERMP1	SSMEM1	psi-mi:“MI:0915”(physical association)	0.560
LYPD5	ERMP1	psi-mi:“MI:0915”(physical association)	0.560
AQP2	ERMP1	psi-mi:“MI:0915”(physical association)	0.560
IFNGR2	ERMP1	psi-mi:“MI:0915”(physical association)	0.560
ERMP1	MR1	psi-mi:“MI:0915”(physical association)	0.560
CLDN7	ERMP1	psi-mi:“MI:0915”(physical association)	0.560
HIBADH	ERMP1	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (220): ERMP1 (Affinity Capture-MS), ERMP1 (Affinity Capture-MS), ERMP1 (Affinity Capture-MS), ERMP1 (Affinity Capture-MS), ERMP1 (Affinity Capture-MS), ERMP1 (Affinity Capture-MS), ERMP1 (Affinity Capture-MS), ERMP1 (Affinity Capture-MS), ERMP1 (Co-fractionation), ERMP1 (Affinity Capture-MS), ERMP1 (Affinity Capture-MS), ERMP1 (Affinity Capture-MS), ERMP1 (Affinity Capture-MS), ERMP1 (Affinity Capture-MS), ERMP1 (Affinity Capture-MS)

ESM2 similar proteins: A0A1D6L709, A2XYW8, A3ACF3, F4JJH5, F4KEL0, O43023, O54697, O64481, P47161, P52708, P91406, Q0DCM5, Q0DM48, Q0J930, Q0JJD4, Q1PDX5, Q2KNB4, Q2KNB7, Q3UVK0, Q43763, Q53NL5, Q5NAT0, Q5WN23, Q5Z678, Q5Z8T8, Q6Z398, Q6ZLK0, Q7M758, Q7Y228, Q7Z2K6, Q84WS0, Q852M4, Q8GUK4, Q8H3C9, Q8H7L6, Q8LH82, Q8RUV9, Q90997, Q9FIG1, Q9FIG2

Diamond homologs: A1CR68, A1D432, A2RAN5, A3LW86, A4R254, A6QS12, A6S8A1, A7F4S1, A8N513, B0DC53, B0XPG0, B2B585, B2W0S3, B6H1I3, B6K327, B6Q656, B8M853, B8NSP6, B9WCV6, C0NU79, C0S345, C1G0X0, C1GTI3, C4YS59, C5FDH0, C5G8H4, C5JPM9, C5M545, C5P998, C6H1N5, C7Z274, C8V4D5, C9SXB4, D1ZV85, D4AMV1, D4D8C1, D5GI81, D8QAM0, E3Q4R4, E3RFJ1

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
ERMP1	“up-regulates activity”	UPR

Disease & clinical

Clinical variants and AI predictions

ClinVar

159 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	0
Uncertain significance	132
Likely benign	4
Benign	5

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
815188	GRCh37/hg19 9p24.3-23(chr9:203861-14103730)x1	Pathogenic
815189	GRCh37/hg19 9p24.3-23(chr9:203861-14080419)x1	Pathogenic

SpliceAI

4357 predictions. Top by Δscore:

Variant	Effect	Δscore
9:5753198:A:AG	acceptor_gain	1.0000
9:5753199:G:GG	acceptor_gain	1.0000
9:5753236:CGGGT:C	donor_loss	1.0000
9:5753237:GG:G	donor_gain	1.0000
9:5753238:GG:G	donor_gain	1.0000
9:5753238:GGTG:G	donor_loss	1.0000
9:5753239:G:C	donor_loss	1.0000
9:5753240:T:G	donor_loss	1.0000
9:5753534:A:AG	acceptor_gain	1.0000
9:5753535:G:GG	acceptor_gain	1.0000
9:5754931:G:GA	donor_loss	1.0000
9:5754932:T:TC	donor_loss	1.0000
9:5756210:A:AG	acceptor_gain	1.0000
9:5756211:G:GA	acceptor_gain	1.0000
9:5756211:GC:G	acceptor_gain	1.0000
9:5756211:GCT:G	acceptor_gain	1.0000
9:5756211:GCTT:G	acceptor_gain	1.0000
9:5756211:GCTTA:G	acceptor_gain	1.0000
9:5756368:GATGG:G	donor_gain	1.0000
9:5756369:ATGGG:A	donor_loss	1.0000
9:5756370:TGGGT:T	donor_loss	1.0000
9:5756371:GG:G	donor_gain	1.0000
9:5756371:GGGTA:G	donor_loss	1.0000
9:5756372:GG:G	donor_gain	1.0000
9:5756372:GGTA:G	donor_loss	1.0000
9:5756373:G:GG	donor_gain	1.0000
9:5756373:GTAA:G	donor_loss	1.0000
9:5756374:T:G	donor_loss	1.0000
9:5757311:A:AG	acceptor_gain	1.0000
9:5757312:G:GA	acceptor_gain	1.0000

AlphaMissense

5910 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:5812177:G:C	H354Q	1.000
9:5812177:G:T	H354Q	1.000
9:5812179:G:C	H354D	1.000
9:5812179:G:T	H354N	1.000
9:5812205:G:T	A345D	1.000
9:5812924:T:A	D329V	1.000
9:5812927:G:A	T328I	1.000
9:5812953:A:C	F319L	1.000
9:5812953:A:T	F319L	1.000
9:5812954:A:C	F319C	1.000
9:5812955:A:G	F319L	1.000
9:5823903:G:C	F289L	1.000
9:5823903:G:T	F289L	1.000
9:5823904:A:G	F289S	1.000
9:5823905:A:G	F289L	1.000
9:5823928:C:T	G281D	1.000
9:5823937:T:A	E278V	1.000
9:5825105:T:A	E252V	1.000
9:5825107:C:A	E251D	1.000
9:5825107:C:G	E251D	1.000
9:5825108:T:A	E251V	1.000
9:5825209:A:C	D217E	1.000
9:5825209:A:T	D217E	1.000
9:5825210:T:A	D217V	1.000
9:5825210:T:G	D217A	1.000
9:5825211:C:A	D217Y	1.000
9:5825211:C:G	D217H	1.000
9:5801188:T:A	R685S	0.999
9:5801188:T:G	R685S	0.999
9:5805105:T:A	R612S	0.999

dbSNP variants (sampled 300 via entrez): RS1000026131 (9:5793429 G>A,C), RS1000041524 (9:5827790 G>A,C), RS1000054927 (9:5809540 CTT>C,CTTT), RS1000148524 (9:5851282 C>T), RS1000162158 (9:5814470 C>A), RS1000170766 (9:5847386 A>G), RS1000179226 (9:5814642 A>C), RS1000198080 (9:5828006 A>G), RS1000218699 (9:5860593 T>G), RS1000226338 (9:5809359 T>G), RS1000272188 (9:5855532 C>T), RS1000280395 (9:5809682 T>C), RS1000364678 (9:5832234 G>A), RS1000365202 (9:5865423 G>A), RS1000396451 (9:5865317 T>C)

Disease associations

OMIM: gene MIM:611156 | disease phenotypes: MIM:209850

GenCC curated gene-disease

Mondo (1): autism (MONDO:0005260)

Orphanet (0):

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0000717	Autism

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST006988_120	Blond vs. brown/black hair color	6.000000e-11
GCST008155_52	Waist-hip ratio	4.000000e-06
GCST008916_119	Asthma	1.000000e-15
GCST009798_74	Asthma	2.000000e-15

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0003924	hair color
EFO:0004343	waist-hip ratio

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D001321	Autistic Disorder	F03.625.164.113.500

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6066506 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
5.40	Kd	3993	nM	CHEMBL5653589
5.34	ED50	4553	nM	CHEMBL5653589

PubChem BioAssay actives

1 with measured affinity, of 2 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148335: Binding affinity to human ERMP1 incubated for 45 mins by Kinobead based pull down assay	kd	3.9935	uM

CTD chemical–gene interactions

39 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, affects expression, affects cotreatment	6
trichostatin A	affects cotreatment, increases expression	3
Tetrachlorodibenzodioxin	affects expression, decreases expression	3
Cyclosporine	decreases expression	3
Cadmium Chloride	decreases expression, increases abundance, increases expression	3
methylmercuric chloride	decreases expression	2
perfluorooctanoic acid	decreases expression	2
Calcitriol	increases expression	2
aristolochic acid I	decreases expression	1
GSK-J4	increases expression	1
FR900359	increases phosphorylation	1
bufotalin	decreases expression	1
triphenyl phosphate	affects expression	1
arsenite	affects binding, decreases reaction	1
potassium chromate(VI)	increases expression	1
perfluorooctane sulfonic acid	decreases expression	1
perfluoro-n-nonanoic acid	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	increases expression, affects cotreatment	1
perfluorohexanesulfonic acid	decreases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
Decitabine	affects expression	1
Sunitinib	decreases expression	1
Arsenic	affects expression	1
Atrazine	increases expression	1
Benzo(a)pyrene	decreases expression	1
Cadmium	increases abundance, increases expression	1
Cisplatin	affects expression	1
Diuron	decreases expression	1
Ivermectin	decreases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5651377	Binding	Binding affinity to human ERMP1 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1RI	Abcam HeLa ERMP1 KO	Cancer cell line	Female

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00211796	PHASE4	COMPLETED	Divalproex Sodium ER in Adult Autism
NCT00391261	PHASE4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT00409747	PHASE4	COMPLETED	Minocycline to Treat Childhood Regressive Autism
NCT00576732	PHASE4	COMPLETED	A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder
NCT00844753	PHASE4	COMPLETED	Atomoxetine, Placebo and Parent Management Training in Autism
NCT01028820	PHASE4	COMPLETED	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
NCT01098383	PHASE4	UNKNOWN	Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Spectrum Disorders
NCT01333865	PHASE4	COMPLETED	A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
NCT01337700	PHASE4	COMPLETED	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
NCT01695200	PHASE4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT02069977	PHASE4	UNKNOWN	Study to Evaluate the Efficacy and Safety of Aripiprazole
NCT02096952	PHASE4	COMPLETED	Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02199925	PHASE4	UNKNOWN	An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum
NCT02235467	PHASE4	COMPLETED	Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism
NCT02255565	PHASE4	COMPLETED	Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study
NCT02940574	PHASE4	COMPLETED	Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03333629	PHASE4	COMPLETED	Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes
NCT03337646	PHASE4	COMPLETED	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
NCT03538431	PHASE4	COMPLETED	Improving Driving in Young People With Autism Spectrum Disorders
NCT03757585	PHASE4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT04903353	PHASE4	COMPLETED	Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT05063656	PHASE4	COMPLETED	Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
NCT05146245	PHASE4	UNKNOWN	Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
NCT05916339	PHASE4	RECRUITING	AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05954052	PHASE4	TERMINATED	A Study of Glutathione in Children With Autism Spectrum Disorder
NCT06853665	PHASE4	RECRUITING	The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT07054697	PHASE4	COMPLETED	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder
NCT07161804	PHASE4	COMPLETED	Pilot RCT Using Homeopathic Medicines in ASD
NCT07439042	PHASE4	NOT_YET_RECRUITING	Buspirone for Anxiety in Autistic Youth
NCT00036231	PHASE3	TERMINATED	Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction
NCT00036244	PHASE3	COMPLETED	Synthetic Human Secretin in Children With Autism
NCT00065884	PHASE3	UNKNOWN	Valproate Response in Aggressive Autistic Adolescents
NCT00065962	PHASE3	COMPLETED	Secretin for the Treatment of Autism
NCT00252603	PHASE3	COMPLETED	Galantamine Versus Placebo in Childhood Autism
NCT00346736	PHASE3	COMPLETED	Use of Acupuncture In Children With Autistic Spectrum Disorder
NCT00352248	PHASE3	COMPLETED	Randomized Controlled Trial of Acupuncture Versus Sham Acupuncture in Autistic Spectrum Disorder
NCT00352352	PHASE3	COMPLETED	Use of Acupuncture In Children With Autistic Spectrum Disorder
NCT00355329	PHASE3	COMPLETED	Randomized Control Trial of Using Tongue Acupuncture in Autistic Spectrum Disorder Using PET Scan for Clinical Correlation
NCT00498173	PHASE3	COMPLETED	Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism
NCT00541346	PHASE3	COMPLETED	A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms